SPRINT试验中CKD患者尿肾小管损伤标志物与肾功能下降的关系
在SPRINT试验的2428例非糖尿病CKD患者中,基线尿KIM-1、MCP-1和YKL-40最高四分位与肾脏复合结局风险升高相关,IL-18是唯一与eGFR下降相关的标志物。
要点
- 尿KIM-1、MCP-1、YKL-40最高四分位与肾脏复合结局风险升高独立相关。
- 尿IL-18最高四分位与eGFR年下降相关,在标准降压组更强。
- 尿小管损伤标志物可提供超越eGFR和尿白蛋白的风险信息。
核心结论
- 尿肾小管细胞损伤标志物可提供超越eGFR和尿白蛋白的后续肾功能丧失风险信息。
研究设计与样本
- SPRINT试验中2428例基线eGFR<60 ml/min per 1.73 m2的CKD患者,中位随访3.8年。
主要发现
- 随访期间发生87例肾脏复合结局事件(50% eGFR下降或需透析/移植的ESKD)。
- 完全调整基线eGFR和尿白蛋白后,尿KIM-1最高四分位与肾脏复合结局风险升高相关(HR 2.84;95%CI 1.31-6.17)。
- 尿MCP-1最高四分位与肾脏复合结局风险升高相关(HR 2.43;95%CI 1.13-5.23)。
- 尿YKL-40最高四分位与肾脏复合结局风险升高相关(HR 1.95;95%CI 1.08-3.51)。
- 尿IL-18最高四分位与eGFR年下降相关(-0.91 ml/min per 1.73 m2/年;95%CI -1.44至-0.38),在标准降压组更强。
临床怎么用
- 在非糖尿病CKD患者中,可考虑检测尿KIM-1、MCP-1、YKL-40和IL-18以辅助风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: eGFR and albuminuria primarily reflect glomerular function and injury, whereas tubule cell atrophy and interstitial fibrosis on kidney biopsy are important risk markers for CKD progression. Kidney tubule injury markers have primarily been studied in hospitalized AKI. Here, we examined the association between urinary kidney tubule injury markers at baseline with subsequent loss of kidney function in persons with nondiabetic CKD who participated in the Systolic Blood Pressure Intervention Trial (SPRINT). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 2428 SPRINT participants with CKD (eGFR<60 ml/min per 1.73 m2) at baseline, we measured urine markers of tubule injury (IL-18, kidney injury molecule-1 [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL]), inflammation (monocyte chemoattractant protein-1 [MCP-1]), and repair (human cartilage glycoprotein-40 [YKL-40]). Cox proportional hazards models evaluated associations of these markers with the kidney composite outcome of 50% eGFR decline or ESKD requiring dialysis or kidney transplantation, and linear mixed models evaluated annualized change in eGFR. RESULTS: Mean participant age was 73±9 (SD) years, 60% were men, 66% were white, and mean baseline eGFR was 46±11 ml/min per 1.73 m2. There were 87 kidney composite outcome events during a median follow-up of 3.8 years. Relative to the respective lowest quartiles, the highest quartiles of urinary KIM-1 (hazard ratio, 2.84; 95% confidence interval [95% CI], 1.31 to 6.17), MCP-1 (hazard ratio, 2.43; 95% CI, 1.13 to 5.23), and YKL-40 (hazard ratio, 1.95; 95% CI, 1.08 to 3.51) were associated with higher risk of the kidney composite outcome in fully adjusted models including baseline eGFR and urine albumin. In linear analysis, urinary IL-18 was the only marker associated with eGFR decline (-0.91 ml/min per 1.73 m2 per year for highest versus lowest quartile; 95% CI, -1.44 to -0.38), a finding that was stronger in the standard arm of SPRINT. CONCLUSIONS: Urine markers of tubule cell injury provide information about risk of subsequent loss of kidney function, beyond the eGFR and urine albumin.
引用
- Malhotra R, Katz R, Jotwani V, et al. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. Clin J Am Soc Nephrol. 2020. PMID: 32111704. doi:10.2215/CJN.02780319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。